Shattuck Labs Announces Participation in the BTIG Biotechnology Conference

Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, will participate in the BTIG Biotechnology Conference on August 10, 2021. The event will feature a fireside chat with CEO Taylor Schreiber, CMO Lini Pandite, and CFO Andrew Neill at 1:30 p.m. EST. Shattuck focuses on developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program, SL-172154, currently in a Phase 1 trial. Another compound, SL-279252, is in Phase 1 trials in collaboration with Takeda Pharmaceuticals.

Positive

• Participation in BTIG Biotechnology Conference highlights company visibility.
• Leadership presentation by key executives signals investor engagement.
• Advancement of lead program SL-172154 and collaboration with Takeda may enhance development prospects.

Negative

• None.

AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021.

Presentation Details
Conference: BTIG Biotechnology Conference
Format: Fireside Chat
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, Lini Pandite, MBChB, M.B.A, Shattuck’s Chief Medical Officer, and Andrew Neill, M.B.A, Shattuck’s Chief Financial Officer
Date: August 10, 2021
Time: 1:30 p.m. EST

The live webcast will be available on BTIG’s conference website at the time of the event, and a replay will be available through BTIG’s research access.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com 

FAQ

What is the significance of Shattuck Labs' participation in the BTIG Biotechnology Conference?

Shattuck Labs' participation in the BTIG Biotechnology Conference on August 10, 2021, signifies an opportunity for increased visibility and engagement with investors.

When is Shattuck Labs' presentation at the BTIG Biotechnology Conference?

Shattuck Labs' presentation at the BTIG Biotechnology Conference is scheduled for August 10, 2021, at 1:30 p.m. EST.

What are the key programs Shattuck Labs is focusing on?

Shattuck Labs is focusing on developing bi-functional fusion proteins for cancer and autoimmune diseases, with lead programs SL-172154 and SL-279252 currently in Phase 1 trials.

Who are the presenters at Shattuck Labs' conference session?

The presenters at Shattuck Labs' conference session include CEO Taylor Schreiber, CMO Lini Pandite, and CFO Andrew Neill.